滋肾安神汤联合生长激素对卵巢储备功能减退患者体外受精-胚胎移植临床结局的影响

doi:10.3969/j.issn.1006-5725.2025.20.019

Abstract

Abstract:

Objective To investigate the effect of joint of Zishen Anshen Tang and growth hormone on the clinical outcomes of in vitro fertilization embryo transfer （IVF-ET） in patients with decreased ovarian reserve function （DOR）. Methods A clinical trial was conducted on 108 DOR patients who underwent IVF-ET at the Reproductive Center of from January 2023 to August 2024. They were randomly assigned to a control group and a experimental group， each with 54. The control group was given growth hormone （GH）， while the experimental group was additionally given Zishen Anshen Tang. The ovulation induction status， trigger day hormone levels， egg retrieval and embryo development， and clinical outcomes were compared. Results The duration of gonadotropin （Gn） use showed no great difference between two groups （P>0.05）. The experimental group had lower Gn dosage， early LH peak rate， and luteinizing hormone （LH）， higher estradiol （E2）， progesterone （P）， egg retrieval， 2PN fertilization， available embryos， number of high-quality embryos on day 3， blastocyst formation rate， clinical pregnancy rate， and cumulative pregnancy rate， and a lower cycle cancellation rate than control group （P<0.05）. Conclusion The joint of Zishen Anshen Tang and growth hormone for IVF-ET in DOR patients can improve their sex hormone and have a positive impact on clinical outcomes.

Key words: Zishen Anshen Tang, growth hormone, decreased ovarian reserve function, in vitro fertilization ? embryo transfer, clinical outcome

CLC Number:

R711.75

Xuan LI,Rong LIN,Jiawen SU,Dunmin. YE. Effect of Zishen Anshen Tang combined with growth hormone on clinical outcomes of in vitro fertilization embryo transfer in patients with decreased ovarian reserve function[J]. The Journal of Practical Medicine, 2025, 41(20): 3283-3287.

Figures/Tables 5

Tab.1

Tab.2

Tab.3

Tab.4

Tab.5

References 24

[1]	JIAO X， MENG T， ZHAI Y， et al. Ovarian Reserve Markers in Premature Ovarian Insufficiency： Within Different Clinical Stages and Different Etiologies［J］. Front Endocrinol （Lausanne）， 2021， 12： 601752. doi:10.3389/fendo.2021.601752 doi: 10.3389/fendo.2021.601752
[2]	SHOARISHOAR S S， KABOODMEHR R， FAKOR F， et al. Assessment of decreased ovarian reserve and systemic inflammatory markers［J］. Cell Mol Biol （Noisy-le-grand）， 2024， 70（11）： 144-149. doi:10.14715/cmb/2024.70.11.21 doi: 10.14715/cmb/2024.70.11.21
[3]	全松，王哲. 重视体外受精-胚胎移植反复种植失败的规范化诊治［J］. 实用医学杂志， 2023， 39（21）： 2693-2697.
[4]	CHEN J， KONG X， LUAN Z， et al. The effects of growth hormone on the outcomes of in vitro fertilization and embryo transfer in age-grouped patients with decreased ovarian reserve： A prospective cohort study［J］. Front Endocrinol （Lausanne）， 2025， 15： 1457866. doi:10.3389/fendo.2024.1457866 doi: 10.3389/fendo.2024.1457866
[5]	PARIKN F R， UTTAMCHANDANI S， SAWKAR S， et al. The impact of follicular fluid phthalate metabolites on the ovarian reserve and ovarian function in Indian women undergoing intracytoplasmic sperm injection［J］. F S Sci， 2024， 5（2）： 107-120.. doi:10.1016/j.xfss.2023.11.001 doi: 10.1016/j.xfss.2023.11.001
[6]	QIN X， DU J， HE R， et al. Adverse effects of type 2 diabetes mellitus on ovarian reserve and pregnancy outcomes during the assisted reproductive technology process［J］. Front Endocrinol （Lausanne），2023， 14： 1274327. doi:10.3389/fendo.2023.1274327 doi: 10.3389/fendo.2023.1274327
[7]	卵巢储备功能减退临床诊治专家共识专家组，中华预防医学会生育力保护分会生殖内分泌生育保护学组. 卵巢储备功能减退临床诊治专家共识［J］. 生殖医学杂志， 2022， 31（4）： 425-434.
[8]	ZHANG Q L， LEI Y L， DENG Y， et al. Treatment Progress in Diminished Ovarian Reserve： Western and Chinese Medicine［J］. Chin J Integr Med， 2023， 29（4）： 361-367. doi:10.1007/s11655-021-3353-2 doi: 10.1007/s11655-021-3353-2
[9]	AIBORZI S， MADADI G， SAMSAMI A， et al. Decreased ovarian reserve： Any new hope？［J］.Minerva Ginecol， 2015， 67（2）： 149-167.
[10]	LELE P R， NAGARAJA N， SINGH Y， et al. Characteristics of Empty Follicular Syndrome during In vitro Fertilization Embryo Transfer and its Association with Various Etiologies in Comparatively Young Patients［J］. J Hum Reprod Sci， 2020， 13（1）： 51-55. doi:10.4103/jhrs.jhrs_96_19 doi: 10.4103/jhrs.jhrs_96_19
[11]	王世铭，祁琳，刘亚平，等.内膜厚度与体外受精-胚胎移植妊娠结局的研究进展［J］.实用医学杂志， 2023， 39（21）： 2698-2703.
[12]	DUAN W， CHENG Y. Sequential therapy for kidney-tonifying via traditional Chinese medicine effectively improves the reproductive potential and quality of life of women with decreased ovarian reserve： A randomized controlled study［J］. Am J Transl Res， 2021， 13（4）： 3165-3173.
[13]	LI H X， SHI L， LIANG S J， et al. Moxibustion alleviates decreased ovarian reserve in rats by restoring the PI3K/AKT signaling pathway［J］. J Integr Med， 2022， 20（2）： 163-172. doi:10.1016/j.joim.2022.01.007 doi: 10.1016/j.joim.2022.01.007
[14]	ZHANG X， ZHANG N， DONG Z， et al. The role of Chinese herbal medicine in diminished ovarian reserve management［J］. J Ovarian Res， 2025， 18（1）： 90. doi:10.1186/s13048-025-01669-4 doi: 10.1186/s13048-025-01669-4
[15]	LIU Y， WEI M， DENG Y， et al. Advances in Traditional Chinese Medicine for Managing Diminished Ovarian Reserve： Mechanisms and Clinical Insights［J］. Drug Des Devel Ther， 2025， 19： 5597-5614. doi:10.2147/dddt.s505689 doi: 10.2147/dddt.s505689
[16]	LV Z， LV Z， SONG L， et al. Role of lncRNAs in the pathogenic mechanism of human decreased ovarian reserve［J］. Front Genet， 2023， 14： 1056061. doi:10.3389/fgene.2023.1056061 doi: 10.3389/fgene.2023.1056061
[17]	KARAKAS E， YAVUZ A， KARAKAS E， et al. Impact of mRNA and Inactivated COVID-19 Vaccines on Ovarian Reserve［J］. Vaccines （Basel）， 2025， 13（4）： 345. doi:10.3390/vaccines13040345 doi: 10.3390/vaccines13040345
[18]	SCANTAMBURLO V M， LINSINGEN R V， CENTA L J R， et al. Association between decreased ovarian reserve and poor oocyte quality［J］. Obstet Gynecol Sci， 2021， 64（6）： 532-539. doi:10.5468/ogs.20168 doi: 10.5468/ogs.20168
[19]	FOULON A， RICHARD N， GUICHARD C， et al. Factors associated with decreased ovarian reserve in Crohn's disease： A systematic review and meta-analysis［J］. Acta Obstet Gynecol Scand， 2024， 103（9）： 1714-1721. doi:10.1111/aogs.14853 doi: 10.1111/aogs.14853
[20]	ÉLISA M， KONYA M， KEKK Z， et al. Platelet-rich plasma （PRP） treatment of the ovaries significantly improves fertility parameters and reproductive outcomes in diminished ovarian reserve patients： A systematic review and meta-analysis［J］. J Ovarian Res， 2024， 17（1）： 104. doi:10.1186/s13048-024-01423-2 doi: 10.1186/s13048-024-01423-2
[21]	LIN G， LIU X， CONG C， et al. Clinical efficacy of acupuncture for diminished ovarian reserve： A systematic review and meta-analysis of randomized controlled trials［J］. Front Endocrinol， 2023， 14： 1136121. doi:10.3389/fendo.2023.1136121 doi: 10.3389/fendo.2023.1136121
[22]	QI Q， ZHANG X， YAO L， et al. Pueratin improves diminished ovarian reserve by inhibiting apoptosis［J］. Exp Ther Med， 2021， 22（6）： 1423. doi:10.3892/etm.2021.10858 doi: 10.3892/etm.2021.10858
[23]	王莉娜，赵艳，于文竹，等. 卵巢囊肿剥除术对卵巢储备功能及辅助生殖治疗的影响［J］. 中华妇产科杂志， 2023， 58（2）： 98-104.
[24]	WU M， ZHU Q， HUANG Y， et al. Ovarian reserve in reproductive-aged patients with cancer before gonadotoxic treatment： A systematic review and meta-analysis［J］. Hum Reprod Open， 2023， 2023（3）： hoad024. doi:10.1093/hropen/hoad024 doi: 10.1093/hropen/hoad024

组别	年龄/岁	体质量指数/（kg/m²）	不孕时间/年	AMH/（ng/mL）	AFC/个	FSH/（IU/L）	LH/（IU/L）
对照组（n=54）	33.28 ± 3.71	22.06 ± 2.26	6.27 ± 0.67	0.83 ± 0.11	3.24 ± 0.39	12.96 ± 1.52	5.17 ± 0.57
观察组（n=54）	33.16 ± 3.62	22.14 ± 2.35	6.33 ± 0.70	0.87 ± 0.14	3.18 ± 0.37	13.05 ± 1.61	5.14 ± 0.54
t值	0.170	0.180	0.455	1.651	0.820	0.299	0.281
P值	0.865	0.857	0.650	0.102	0.414	0.766	0.779

组别	Gn使用天数/d	Gn用量/IU	早发LH峰率/[例（%）]
对照组（n = 54）	9.06 ± 0.96	2741.91 ± 296.33	10（18.52）
观察组（n = 54）	8.92 ± 0.92	2230.14 ± 226.79	2（3.70）
χ2/t值	0.774	10.078	6.000
P值	0.441	< 0.001	0.014

组别	LH/（IU/L）	E2/（pg/mL）	P/（ng/mL）
对照组（n=54）	5.11 ± 0.56	1105.16 ± 119.91	0.77 ± 0.11
观察组（n=54）	3.71 ± 0.42	1354.21 ± 154.77	0.89 ± 0.15
t值	14.679	9.348	4.741
P值	< 0.001	< 0.001	< 0.001

组别	获卵数/个	2PN受精数/个	可利用胚胎数/个	第3天的优质胚胎数/个
对照组	3.76 ± 0.43	2.68 ± 0.35	1.73 ± 0.21	1.62 ± 0.19
观察组	4.25 ± 0.48	3.27 ± 0.40	2.15 ± 0.25	1.89 ± 0.23
t值	5.587	8.157	9.453	6.651
P值	< 0.001	< 0.001	< 0.001	< 0.001

组别	囊胚形成率	周期取消率	临床妊娠率	累积妊娠率
对照组（n = 54）	26（48.15）	17（31.48）	41（75.93）	30（55.56）
观察组（n = 54）	37（68.52）	8（14.81）	50（92.59）	40（74.07）
χ2值	4.610	4.216	5.655	4.060
P值	0.032	0.040	0.017	0.044

Effect of Zishen Anshen Tang combined with growth hormone on clinical outcomes of in vitro fertilization embryo transfer in patients with decreased ovarian reserve function

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 24

Related Articles 4

Recommended Articles

Metrics

Comments

[1]	Lijuan CHEN,Bin LI,Lixin. YANG. Effect of lysine inositol vitamin B₁₂ oral solution combined with rhGH on bone mineral density and insulin growth factor in children with idiopathic dwarfism [J]. The Journal of Practical Medicine, 2025, 41(5): 731-735.
[2]	CHEN Xiao, CUI Yu⁃ anyuan, TAN Ying, LIN Sheng, HE Yichao, ZHANG Qingjian, SONG Ge. . The predictive value of IGF⁃1 in D⁃IVF taking mid⁃luteal phase GnRHa protocol [J]. The Journal of Practical Medicine, 2022, 38(13): 1642-1646.
[3]	MO Man⁃ qiu, PAN Ling, YANG Zhenhua, QIN Kangna, ZHANG Jiliang, LIAO Yunhua, HUO Dongmei.. Association between high density lipoprotein and clinical outcomes in peritoneal dialysis patients [J]. The Journal of Practical Medicine, 2021, 37(15): 1934-1938.
[4]	SUN Xian, JIANG Hong, LIU Yingchun, NI Feng, ZHU Jie. . R711.6 Clinical application value of oocyte vitrification [J]. The Journal of Practical Medicine, 2021, 37(11): 1423-1427.